N-aspartyl chlorin e6


  • Photosensitizer: N-aspartyl chlorin e6
  • Tradename: NPe6
  • Company Photosensitizer: Nippon Petrochemical
  • Clinical Application: Endobronchial lung cancer and cutaneous malignancies
  • Wavelength (nm): 664
  • Extinction Coefficient (M-1 cm-1): 4.0 104
  • Mode of Delivery: Intravenous
  • Delivery vehicle: Water-soluble
  • Typical Dose (mg kg-1): 0.5–3.5
  • Light Dose (J cm-2): 25–100
  • Time Post-Injection: 4 h
  • Duration of Skin Photosensitivity: 3–7 days

Under the supervision of Nippon Petrochemical (Osaka, Japan), N-aspartyl chlorin e6 (NPe6) is being studied as a possible photosensitizer for PDT [93]. Phase I clinical trials are under way for the treatment of cutaneous malignancies[69] and it is also being investigated in Japan as a possible therapy for endobronchial lung cancer. Npe6 has been shown to be an effective photosensitizer against skin cancers with little or no long-term cutaneous photosensitivity.
The photodynamic activity of Npe6 also involves a combination of vascular (indirect effect) and direct anti-tumour photodamage, which is another potential advantage of this photosensitizer[94].



N-aspartyl chlorin e6

Index